Table 2.
Internally replicated proteins that are specific to BMI or WHR (n = 4203)a
| BMI | WHR | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Proteins | N | β (SE) | FDR-adjusted P1b | FDR-adjusted P2c | Proteins | N | β (SE) | FDR-adjusted P1b | FDR-adjusted P2c |
| AM | 4131 | 0.27 (0.02) | 1.00 × 10–30 | 6.11 × 10–07 | PRSS8 | 4198 | 0.10 (0.01) | 2.75 × 10–12 | .00017 |
| IL6 | 4131 | 0.13 (0.02) | 2.43 × 10–14 | .47 | IL18 | 4131 | 0.16 (0.03) | 4.27 × 10–07 | .0069 |
| TNFR1 | 4131 | 0.17 (0.02) | 3.70 × 10–22 | .05 | CCL20 | 4131 | 0.16 (0.03) | 5.07 × 10–07 | .0074 |
| CSF1 | 4131 | 0.15 (0.02) | 9.26 × 10–17 | .1 | CCL4 | 4131 | 0.16 (0.03) | 5.07 × 10–07 | .0029 |
| IL16 | 4131 | 0.14 (0.02) | 1.42 × 10–14 | .068 | IL8 | 4131 | 0.16 (0.03) | 8.40 × 10–07 | 9.44 × 10–05 |
| RAGE | 4131 | –0.16 (0.02) | 2.94 × 10–18 | .05 | CDKN1A | 4091 | 0.13 (0.03) | 2.34 × 10–06 | .0019 |
| GAL | 4131 | –0.15 (0.02) | 8.48 × 10–17 | .0051 | CXCL6 | 4131 | 0.15 (0.03) | 2.95 × 10–06 | .003 |
| VEGFD | 4131 | –0.16 (0.02) | 1.14 × 10–18 | .083 | CXCL11 | 4194 | 0.14 (0.03) | 6.88 × 10–06 | .0019 |
| EMMPRIN | 4198 | 0.04 (0.01) | 6.03 × 10–15 | 2.22 × 10–06 | GDF15 | 4131 | 0.13 (0.03) | 2.95 × 10–06 | .0024 |
| ILT3 | 4179 | 0.05 (0.01) | 1.41 × 10–09 | .71 | CHI3L1 | 4131 | 0.13 (0.03) | 5.48 × 10–06 | .0031 |
| IL12 | 4198 | 0.08 (0.01) | 3.17 × 10–11 | .27 | CA125 | 4131 | 0.14 (0.03) | 1.09 × 10–05 | .0031 |
| TRANCE | 4131 | 0.12 (0.02) | 3.57 × 10–11 | .21 | LAPTGFbeta1 | 4198 | 0.08 (0.02) | 5.27 × 10–06 | .003 |
| EZR | 4121 | 0.04 (0.01) | 9.87 × 10–11 | .05 | CTSL1 | 4131 | 0.13 (0.03) | 1.59 × 10–05 | .039 |
| TNFR2 | 4131 | 0.11 (0.02) | 8.66 × 10–10 | .55 | TNFSF14 | 4131 | 0.12 (0.03) | .00016 | .075 |
| ESM1 | 4131 | –0.11 (0.02) | 8.66 × 10–10 | .18 | CASP3 | 4131 | 0.12 (0.03) | 7.42 × 10–05 | .003 |
| MB | 4131 | 0.09 (0.02) | 6.22 × 10–08 | .068 | CXCL5 | 4198 | 0.11 (0.03) | .00013 | .0046 |
| TRAIL | 4131 | 0.10 (0.02) | 6.54 × 10–08 | .52 | HBEGF | 4131 | 0.12 (0.03) | .00013 | .0079 |
| FRalpha | 4198 | –0.05 (0.01) | 5.19 × 10–08 | .21 | CXCL13 | 4128 | 0.08 (0.02) | 8.34 × 10–05 | .012 |
| KLK6 | 4131 | –0.10 (0.02) | 5.19 × 10–08 | .024 | IL7 | 4149 | 0.07 (0.02) | .00024 | .0074 |
| Gal3 | 4131 | 0.10 (0.02) | 4.11 × 10–08 | .016 | Dkk1 | 4131 | 0.11 (0.03) | .00045 | .003 |
| NTRK3 | 4198 | –0.04 (0.01) | 3.10 × 10–08 | .67 | MMP7 | 4131 | 0.11 (0.03) | .00032 | .0029 |
| hK11 | 4131 | –0.10 (0.02) | 5.33 × 10–08 | .0021 | MICA | 3726 | 0.07 (0.02) | .00056 | .22 |
| TRAILR2 | 4131 | 0.09 (0.02) | 5.19 × 10–08 | .83 | OPG | 4131 | 0.10 (0.03) | .0006 | .0023 |
| MMP10 | 4131 | –0.10 (0.02) | 2.47 × 10–08 | .0051 | SRC | 4131 | -0.11 (0.03) | .00032 | .003 |
| HE4 | 4198 | –0.04 (0.01) | 6.16 × 10–08 | .00047 | |||||
| REG4 | 4198 | –0.04 (0.01) | 4.88 × 10–07 | .016 | |||||
| PTX3 | 4131 | –0.08 (0.02) | 6.73 × 10–06 | .13 | |||||
| mAmP | 4131 | –0.09 (0.02) | 2.41 × 10–06 | .00075 | |||||
| ITGA1 | 4198 | –0.03 (0.01) | 6.99 × 10–05 | .73 | |||||
| ECP | 4131 | 0.07 (0.02) | 5.15 × 10–05 | .73 | |||||
| ErbB4HER4 | 4198 | –0.03 (0.01) | 4.61 × 10–05 | .22 | |||||
| MIA | 4198 | –0.03 (0.01) | 8.10 × 10–05 | .068 | |||||
| TM | 4131 | 0.07 (0.02) | 0.0001 | .55 | |||||
| AGRP | 4131 | –0.07 (0.02) | 8.10 × 10–05 | .18 | |||||
| IL6RA | 4131 | 0.07 (0.02) | 0.00023 | .21 | |||||
| Flt3L | 4198 | 0.03 (0.01) | 0.00028 | .55 | |||||
| SCF | 4131 | –0.06 (0.02) | 0.00042 | .68 | |||||
| MPO | 4131 | 0.06 (0.02) | 0.00093 | .99 | |||||
AGRP, Agouti-related protein; AM, Adrenomedullin; BMI, body mass index; CA125, Ovarian cancer–related tumor marker CA 125; CASP3, Caspase-3; CCL20, C-C motif chemokine 20; CCL4, C-C motif chemokine 4; CDKN1A, Cyclin-dependent kinase inhibitor 1; CHI3L1, Chitinase-3-like protein 1; CSF1, Macrophage colony-stimulating factor 1; CTSL1, Cathepsin L1; CXCL11, C-X-C motif chemokine 11; CXCL13, C-X-C motif chemokine 13; CXCL5, C-X-C motif chemokine 5; CXCL6, C-X-C motif chemokine 6; Dkk1, Dickkopf-related protein 1; ECP, Eosinophil cationic protein; EMMPRIN, Extracellular matrix metalloproteinase inducer; ErbB4HER4, Receptor tyrosine-protein kinase erbB-4; ESM1, Endothelial cell-specific molecule 1; EZR, Ezrin; FDR, false discovery rate; Flt3L, Fms-related tyrosine kinase 3 ligand; FRalpha, Folate receptor alpha; GAL, Galanin peptides; Gal3, Galectin-3; GDF15, Growth/differentiation factor 15; HBEGF, heparin binding epidermal growth factor like growth factor; HE4, Epididymal secretory protein E4; hK11, Kallikrein-11; IL12, Interleukin-12; IL16, Interleukin-16; IL18, Interleukin-18; IL6, Interleukin-6; IL6RA, Interleukin-6 receptor subunit alpha; IL7, Interleukin-7; IL8, Interleukin-8; ILT3, Immunoglobulin-like transcript 3; ITGA1, Integrin alpha-1; KLK6, Kallikrein-6; LAPTGFbeta1, Latency-associated peptide transforming growth factor beta-1; mAmP, Membrane-bound aminopeptidase P; MB, Myoglobin; MIA, Melanoma-derived growth regulatory protein; MICA, MHC class I polypeptide-related sequence A; MMP10, matrix metalloproteinase-10; MMP7, matrix metalloproteinase-7; MPO, Myeloperoxidase; NTRK3, NT-3 growth factor receptor; OPG, Osteoprotegerin; PRSS8, Prostasin; PTX3, Pentraxin-related protein PTX3; RAGE, Receptor for advanced glycosylation end products; REG4, Regenerating islet-derived protein 4; SCF, Stem cell factor; SE, standard error; SRC, Proto-oncogene tyrosine-protein kinase Src; TM, Thrombomodulin; TNFR1, Tumor necrosis factor receptor 1; TNFR2, Tumor necrosis factor receptor 2; TNFSF14, Tumor necrosis factor ligand superfamily member 14; TRAIL, TNF-related apoptosis-inducing ligand; TRAILR2, TNF-related apoptosis-inducing ligand receptor 2; TRANCE, TNF-related activation-induced cytokine; VEGFD, Vascular endothelial growth factor D; WHR, waist-to-hip ratio.
a A protein was considered to be specific to BMI if (1) it was internally replicated to associate with BMI but not WHR and (2) the β coefficient for its association with BMI statistically differed from that for its association with WHR in multivariate linear regressions (and vice versa for proteins specific to WHR). Proteins specific to BMI or WHR were highlighted in bold font.
b Linear regressions with BMI and WHR adjusted for each other in the same model and adjusted for age, sex, smoking, high alcohol consumption, systolic blood pressure, low density lipoprotein, and antihypertensive medication. FDR-adjusted P1 < .05 was used as the cutoff.
c F-tests were conducted to compare if the absolute values for weighs of BMI and WHR, as reflected by β coefficients, differed significantly in multivariate linear regressions. FDR-adjusted P2 < .05 was used as the cutoff.